Preventing Stroke in Patients With Chronic Kidney Disease and Atrial Fibrillation Benefit and Risks of Old and New Oral Anticoagulants

摘要

Chronic kidney disease (CKD) is a major global health problem. It is defined by decreased kidney function (characterized by a reduced estimated glomerular filtration rate [eGFR] <60 mL/min per 1.73 m2) and kidney damage characterized by albuminuria or proteinuria.1 To standardize definitions and facilitate risk stratification, 5 different stages of severity have been defined by the National Kidney Foundation in 2002: CKD stage 1 with a normal eGFR >90 mL/min per 1.73m2 but proven proteinuria, CKD stage 2 with eGFR 60 to 89 mL/min per 1.73 m2, CKD stage 3 with eGFR 30 to 59 mL/min per 1.73 m2, CKD stage 4 with eGFR 15 to 29 mL/min per 1.73 m2, and CKD stage 5 with eGFR <15 mL/min per 1.73 m2.